Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Contact allergy to methylisothiazolinone with three clinical presentations in one patient.

Gorris A, Valencak J, Schremser V, Bangert C, Kinaciyan T.

Contact Dermatitis. 2019 Aug 12. doi: 10.1111/cod.13384. [Epub ahead of print] No abstract available.

PMID:
31403207
2.

Patients' Illness Perception as a Tool to Improve Individual Disease Management in Primary Cutaneous Lymphomas.

Porkert S, Lehner-Baumgartner E, Valencak J, Knobler R, Riedl E, Jonak C.

Acta Derm Venereol. 2018 Feb 7;98(2):240-245. doi: 10.2340/00015555-2819.

3.

High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.

Valencak J, Schmid K, Trautinger F, Wallnöfer W, Muellauer L, Soleiman A, Knobler R, Haitel A, Pehamberger H, Raderer M.

J Dermatol Sci. 2011 Dec;64(3):185-90. doi: 10.1016/j.jdermsci.2011.08.011. Epub 2011 Sep 8.

PMID:
21937200
4.

Dermal infiltrates of cutaneous T-cell lymphomas with epidermotropism but not other cutaneous lymphomas are abundant with langerin⁺ dendritic cells.

Der-Petrossian M, Valencak J, Jonak C, Klosner G, Dani T, Müllauer L, Pehamberger H, Knobler R, Trautinger F.

J Eur Acad Dermatol Venereol. 2011 Aug;25(8):922-7. doi: 10.1111/j.1468-3083.2010.03882.x. Epub 2010 Nov 4.

PMID:
21054571
5.

Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma.

Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, Birner P, Pehamberger H.

Clin Exp Dermatol. 2009 Dec;34(8):e962-4. doi: 10.1111/j.1365-2230.2009.03706.x.

PMID:
20055873
6.

Somatostatin receptor scintigraphy in primary cutaneous T- and B-cell lymphomas.

Valencak J, Trautinger F, Raderer M, Chott A, Der-Petrossian M, Ivancic-Brandenberger E, Knobler R, Kurtaran A, Hoffmann M.

J Eur Acad Dermatol Venereol. 2010 Jan;24(1):13-7. doi: 10.1111/j.1468-3083.2009.03330.x. Epub 2009 Jun 8.

PMID:
19515078
7.

Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.

Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, Streubel B, Muellauer L, Der-Petrossian M, Jonak C, Binder M, Raderer M.

Ann Oncol. 2009 Feb;20(2):326-30. doi: 10.1093/annonc/mdn636. Epub 2008 Oct 3.

PMID:
18836086
8.

Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy.

Valencak J, Troch M, Raderer M.

J Natl Cancer Inst. 2007 Jan 17;99(2):177-8. No abstract available.

PMID:
17228004
9.

Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas.

Streubel B, Scheucher B, Valencak J, Huber D, Petzelbauer P, Trautinger F, Weihsengruber F, Mannhalter C, Cerroni L, Chott A.

Am J Surg Pathol. 2006 Apr;30(4):529-36.

PMID:
16625101
10.

Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses.

Humer J, Waltenberger A, Grassauer A, Kurz M, Valencak J, Rapberger R, Hahn S, Löwer R, Wolff K, Bergmann M, Muster T, Mayer B, Pehamberger H.

Cancer Res. 2006 Feb 1;66(3):1658-63.

11.

Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results.

Valencak J, Heere-Ress E, Traub-Weidinger T, Raderer M, Schneeberger A, Thalhammer T, Aust S, Hamilton G, Virgolini I, Pehamberger H.

Melanoma Res. 2005 Dec;15(6):523-9.

PMID:
16314738
12.

Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas.

Valencak J, Becherer A, Der-Petrossian M, Trautinger F, Raderer M, Hoffmann M.

Haematologica. 2004 Jan;89(1):115-6. No abstract available.

13.

Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma.

Valencak J, Heere-Ress E, Kopp T, Schoppmann SF, Kittler H, Pehamberger H.

Eur J Cancer. 2004 Feb;40(3):358-64.

PMID:
14746853
14.

Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema.

Valencak J, Ortiz-Urda S, Heere-Ress E, Kunstfeld R, Base W.

Int J Dermatol. 2004 Jan;43(1):51-4. No abstract available.

PMID:
14693022
15.

Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxyadenosine.

Valencak J, Trautinger F, Fiebiger WC, Raderer M.

Ann Hematol. 2002 Nov;81(11):662-5. Epub 2002 Oct 29. Review.

PMID:
12454707
16.

Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.

Scheithauer W, Kornek GV, Brugger S, Ullrich-Pur H, Valencak J, Raderer M, Fiebiger W, Kovats E, Lang F, Depisch D.

Cancer Invest. 2002;20(1):60-8.

PMID:
11853004
17.

Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis.

Penz MZ, Fiebiger WC, Valencak JB, Osterreicher C, Ba-Ssalamah A, Formanek M, Brodowic T, Chott A, Raderer M.

Anticancer Res. 2001 Jul-Aug;21(4B):3049-52.

PMID:
11712809
18.

Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma.

Valencak J, Dietrich W, Raderer M, Dieckmann K, Prayer D, Hainfellner JA, Marosi C.

J Neurooncol. 2000 Sep;49(3):263-8. Review.

PMID:
11212906
19.

Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.

Kwasny W, Kornek G, Haider K, Valencak J, Ulrich-Pur H, Penz M, Lang F, Depisch D, Scheithauer W.

Breast Cancer Res Treat. 2000 Oct;63(3):235-41.

PMID:
11110057
20.

Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma.

Raderer M, Vorbeck F, Formanek M, Osterreicher C, Valencak J, Penz M, Kornek G, Hamilton G, Dragosics B, Chott A.

Br J Cancer. 2000 Aug;83(4):454-7.

Supplemental Content

Loading ...
Support Center